Abstract
In a prospective study of 499 patients with suspected coronary artery disease (CAD) hospitalized for coronary angiography, the prevalence of use of cardiovascular drugs at hospital admission was 80% for antiplatelet drugs, 66% for beta blockers, 55% for angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), 65% for lipid-lowering drugs, 24% for calcium channel blockers (CCBs), and 16% for nitrates. In 357 patients with obstructive CAD diagnosed by coronary angiography, the prevalence of use of these drugs at hospital discharge was 100% for antiplatelet drugs, 97% for beta blockers, 91% for ACE inhibitors or ARBs, 98% for lipid-lowering drugs, 17% for CCBs, and 27% for nitrates. Obstructive CAD was significantly more prevalent in men (P < 0.025), in cigarette smokers (P < 0.01), and in patients with hypertension, diabetes, or hypercholesterolemia (P < 0.001). Age, race, body mass index, and neck circumference were not significantly different for patients with versus without obstructive CAD.
MeSH terms
-
Age Factors
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Calcium Channel Blockers / therapeutic use
-
Cardiovascular Agents / administration & dosage
-
Cardiovascular Agents / therapeutic use*
-
Coronary Angiography
-
Coronary Artery Disease / complications
-
Coronary Artery Disease / diagnosis
-
Coronary Artery Disease / drug therapy*
-
Coronary Occlusion / complications
-
Coronary Occlusion / diagnosis
-
Coronary Occlusion / drug therapy
-
Diabetes Complications
-
Drug Utilization
-
Female
-
Hospitalization / statistics & numerical data*
-
Humans
-
Hypercholesterolemia / complications
-
Hypercholesterolemia / drug therapy
-
Hypertension / complications
-
Hypertension / drug therapy
-
Hypolipidemic Agents / therapeutic use
-
Male
-
Middle Aged
-
Platelet Aggregation Inhibitors / therapeutic use
-
Prospective Studies
-
Sex Factors
-
Smoking
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Calcium Channel Blockers
-
Cardiovascular Agents
-
Hypolipidemic Agents
-
Platelet Aggregation Inhibitors